Search Results for

A091901

Additional Support Program Via Text Messaging and Telephone-Based Counseling for Breast Cancer Patients Receiving Hormonal Therapy

Continue Reading »

---

SGNTUC-016

A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer

Continue Reading »

---

EAZ171

Docetaxel or Paclitaxel in Reducing Chemotherapy-Induced Peripheral Neuropathy in African American Patients With Stage I-III Breast Cancer

Continue Reading »

---

URCC-18007

Bupropion in Reducing Cancer Related Fatigue in Stage I-III Breast Cancer Survivors

Continue Reading »

---

MA.39

Regional Radiotherapy in Biomarker Low Risk Node Positive Breast Cancer (TAILOR RT)

Continue Reading »

---

BR004

Paclitaxel, Trastuzumab, and Pertuzumab With or Without Atezolizumab in Treating Patients With Metastatic Breast Cancer

Continue Reading »

---

A171601

Palbociclib and Letrozole or Fulvestrant in Treating Patients With Estrogen Receptor Positive, HER2 Negative Metastatic Breast Cancer

Continue Reading »

---

S1703

Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer

Continue Reading »

---

A221505

Hypofractionated Radiation Therapy After Mastectomy in Preventing Recurrence in Patients With Stage IIa-IIIa Breast Cancer

Continue Reading »

---

AFT-25

Comparison of Operative to Monitoring and Endocrine Therapy (COMET) Trial For Low Risk DCIS

Continue Reading »

---

Search Again

• All Trial Categories Anal  (3) Bladder/Urinary Tract Cancer  (8)    Adjuvant  (1)    Metastatic  (2)    Neoadjuvant  (4) Brain  (7)    Glioblastoma Multiforme (GBM)  (3)    Other Brain Tumors  (3) Breast  (17)    1st Line Metastatic Breast, Metastasis at Presentation or Progression of earlier Disease  (5)    2nd Line Metastatic Breast, Progressive Disease Following 1st Line Therapy  (1)    Breast Cancer Adjuvant  (5)    Breast Cancer Neoadjuvant  (1)    DCIS/LCIS  (1) Cancer Control/Symptom Management  (22) Carcinoid Tumors  (2) Colorectal Cancer  (9)    Metastatic  (4) Esophageal Cancer  (2) Gall Bladder/ Biliary Tract Cancer  (1) Gastric Cancer  (2)    Metastaic Gastric Cancer  (1) Head/Neck Cancer  (4)    Resectable Oral Cavity Cancer  (1)       Primary Chemoradiation Regimens  (1) Leukemia  (9)    Acute Myeloid Leukemia (AML)  (1)    B-Cell Chromic Lymphocytic Leukemia (CLL) / Small Ly  (5) Liver/Hepatocellular Carcinoma  (1) Lung Cancer  (24)    Non-Small Cell Lung Cancer  (19)       1st Line Metastatic, Stage3b with Maligned Effusion or Stage 4 Disease at Presentation or Recurrence  (3)       2nd Line Metastatic, Stage 4 Patients with Progressive Disease  (4)       Adjuvant Treatment for Resected NSCLC  (4)    Small Cell Lung Cancer  (5)       Extensive Stage SCLC  (2) Lymphoma  (9)    Non-Hodgkin’s Lymphoma  (4)       Diffuse Large B-Cell Lymphoma  (1)       Follicular Lymphoma  (2)          Relapsed/Refractory  (2) MATCH Trial  (1) MDS  (3) Melanoma  (7)    Metastatic  (3) Merkel Cell Carcinoma  (1) Multiple Myeloma  (2) Pancreatic  (6)    Metastatic Disease  (4) Prostate  (9) Renal Cell/Kidney Cancer  (6)    Locally Advanced/Metastatic  (4) Sarcoma  (2) Small Bowel  (1)